Clal Insurance Enterprises Holdings LTD Vertex Pharmaceuticals Inc Transaction History

Clal Insurance Enterprises Holdings LTD

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 13, 2023	SELL	$285.76 - $321.48 $13.4 Million - $15.1 Million	-47,000 Reduced 22.14%	165,240 $47.7 Million
Q3 2022 Nov 14, 2022	SELL	$273.83 - $305.53 $1.37 Million - $1.53 Million	-5,000 Reduced 2.3%	212,240 $61.5 Million
Q2 2022 Aug 09, 2022	SELL	$234.96 - $292.55 $11.2 Million - $14 Million	-47,760 Reduced 18.02%	217,240 $61.2 Million
Q1 2022 May 12, 2022	SELL	$221.42 - $260.97 $47.8 Million - $56.4 Million	-216,000 Reduced 44.91%	265,000 $69.2 Million
Q4 2021 Feb 10, 2022	BUY	$177.01 - $223.45 $57.3 Million - $72.3 Million	323,500 Added 205.4%	481,000 $106 Million
Q3 2021 Nov 15, 2021	BUY	$181.39 - $202.99 $27.8 Million - $31.1 Million	153,000 Added 3400.0%	157,500 $28.6 Million
Q2 2021 Aug 11, 2021	BUY	$187.49 - $221.1 $843,705 - $994,950	4,500 New	4,500 $907,000

1,717

226M

1.19M

1.56M

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $133B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

Get notified when there are updates to the investment portfolio of Clal Insurance Enterprises Holdings LTD, based on Form 13F filings with the SEC.

Stay updated on Clal Insurance Enterprises Holdings LTD with notifications on news.